nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

16.02.2018 | Original Article

Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer

verfasst von: Cavit Ceylan, Sedat Yahşi, Serkan Doğan, Elife ÖztÜrk, Gulay Ceylan

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Bladder cancer (BCa) is the seventh most common cancer among males worldwide. Some reliable markers in blood, urine, and tumor tissue, including clinicopathologic variables, molecular and inflammatory markers, gene polymorphisms, and tumor gene expression profiles are identified for predicting response to BCG immunotherapy in high-risk BCa patients.

Aims

We aimed to determine if FAS and FASL polymorphisms are associated with lack of response to BCG in patients with BCa.

Methods

The study included patients with primary non-muscle invasive BCa that had undergone transurethral resection (TUR). Patient demographics, BCa characteristics, use of BCG immunotherapy, lack of response to BCG (if administered), BCa recurrence, and fatty acid synthetase/fatty acid syntethase ligand (FAS/FASL) polymorphisms were investigated.

Results

The study included 127 patients with primary BCa. Mean age of the 107 (84.3%) male and 20 (15.7%) female patients was 59.3 ± 13.2 years. Among the patients that received BCG immunotherapy, more FAS homozygous patients had BCa recurrence than FAS polymorphism-negative patients (P < 0.001) and more patients with homozygote FASL polymorphisms had BCa recurrence than those with heterozygous FASL polymorphisms and no polymorphism.

Conclusion

Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated.

Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Alfred Witjes J, Lebret T, Comperat E et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020 CrossRefPubMed

Zlotta A, Fleshner N, Jewett M (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3(6 Suppl 4):S199–S205PubMedPubMedCentral

Zuiverloon T, Nieuweboer A, Vekony H, Kirkels W, Bangma C, Zwarthoff E (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61(1):128–145. https://doi.org/10.1016/j.eururo.2011.09.026 CrossRefPubMed

Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V (2015) Treatment of non-muscle invasive bladder cancer with bacillus Calmette-Guerin (BCG): biological markers and simulation studies. Bba Clin 4:27–34. https://doi.org/10.1016/j.bbacli.2015.06.002 CrossRefPubMedPubMedCentral

Lima L, Ferreira J, Tavares A et al (2014) FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer. Urol Oncol 32(44):E41–E47

Lima L, Oliveira D, Ferreira J et al (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a southern Europe population. BJU Int 116(5):753–763. https://doi.org/10.1111/bju.12844 CrossRefPubMed

Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z (2013) Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. ScientificWorldJournal 2013:176741CrossRef

Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A (2000) Perforin-mediated lysis of tumor cells by mycobacterium bovis bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6(9):3729–3738PubMed

10.

Zhang N, Jiang G, Liu X, Na R, Wang X, Xu J (2016) Prediction of bacillus Calmette-Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies. Biomed Res Int 2016:9859021PubMedPubMedCentral

11.

Kang H, Tchey D, Yan C et al (2014) The predictive value of Gstt1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Urol Oncol 32(4):458–465. https://doi.org/10.1016/j.urolonc.2013.10.013 CrossRefPubMed

12.

Ahirwar D, Agrahari A, Mandhani A, Mittal R (2009) Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4):213–218. https://doi.org/10.1080/13547500902818246 CrossRefPubMed

13.

Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B (2006) Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Guerin (Bcg) immunotherapy. Cytokine 35(1-2):1–5. https://doi.org/10.1016/j.cyto.2006.06.009 CrossRefPubMed

14.

Gangwar R, Mandhani A, Mittal R (2010) Xpc gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. J Cancer Res Clin Oncol 136(5):779–786. https://doi.org/10.1007/s00432-009-0717-y CrossRefPubMed

15.

Mittal R, Singh R, Manchanda P et al (2008) Xrcc1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther 7(5):645–650. https://doi.org/10.4161/cbt.7.5.5763 CrossRefPubMed

16.

Houston A, O'connell J (2004) The FAS signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4(4):321–326. https://doi.org/10.1016/j.coph.2004.03.008 CrossRefPubMed

17.

Reichmann E (2002) The biological role of the FAS/FASL system during tumor formation and progression. Semin Cancer Biol 12(4):309–315. https://doi.org/10.1016/S1044-579X(02)00017-2 CrossRefPubMed

18.

Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30(3):487–493. https://doi.org/10.1093/carcin/bgp016 CrossRefPubMed

19.

Chopin D, Barei-Moniri R, Maille P et al (2003) Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 162(4):1139–1149. https://doi.org/10.1016/S0002-9440(10)63910-7 CrossRefPubMedPubMedCentral

20.

Li C, Wu W, Liu J, Qian L, Li A, Yang K, Wei Q, Zhou J, Zhang Z (2006 Apr) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in South China: a case-control analysis. Pharmacogenet Genomics 16(4):245–251. https://doi.org/10.1097/01.fpc.0000194425.58511.a7 CrossRefPubMed

21.

Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, Yaylim I, Ergen A, Ozturk O, Isbir T (2014 May-Jun) Functional genetic variants in apoptosis associated Fas and Fasl genes and risk of bladder cancer in a Turkish population. In Vivo 28(3):397–402PubMed

Titel: Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer
verfasst von: Cavit Ceylan
Sedat Yahşi
Serkan Doğan
Elife ÖztÜrk
Gulay Ceylan
Publikationsdatum: 16.02.2018
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 4/2018
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-018-1764-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

A snapshot of type two diabetes mellitus management in general practice prior to the introduction of diabetes Cycle of Care

Child Art Psychotherapy in CAMHS in Ireland—a parent satisfaction study

A comparison of diagnostic performance of vacuum-assisted biopsy and core needle biopsy for breast microcalcification: a systematic review and meta-analysis

Lumbar sympathectomy can improve symptoms associated with ischaemia, vasculitis, diabetic neuropathy and hyperhidrosis affecting the lower extremities—a single-centre experience

A positive conversion in hormone receptor and HER2 status might have an impact on survival after liver resection for breast cancer metastases

Financial impact of inaccurate Adverse Event recording post Hip Fracture surgery: Addendum to 'Adverse event recording post hip fracture surgery'